Oscar Health Announces New Health Insurance Options in New Jersey in 2025 
IRLAB: Invitation to the Interim Report for Q3 2024 Presentation and Webcast
GOTHENBURG, SWEDEN / ACCESSWIRE / October 28, 2024 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing...
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Immunophotonics to Present at the 2024 ThinkEquity Conference
ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development...
Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients HOUSTON, TX, Oct. 28, 2024 (GLOBE...
TOMI Environmental Solutions Announces Preliminary Financial Results for Third Quarter 2024 With Continued Profitability and Global Market Expansion
FREDERICK, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI” or the “Company”) (NASDAQ: TOMZ), a global...
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct....
ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture...
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today...
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies
– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and...
Therma Bright’s Investment Partnership InStatin Joins Forces with InVixa to Enhance Its Patent Portfolio For The Development Of Innovative Respiratory Solutions
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung diseaseToronto, Ontario--(Newsfile...
CluePoints Appoints Richard Young as Chief Strategy Officer
KING OF PRUSSIA, Pa., Oct. 28, 2024 /PRNewswire/ -- RBQM innovator CluePoints has today announced that Richard Young has been...
3Aware and RQM+ Forge Partnership to Enhance MedTech Compliance and Innovation
INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical...
AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis
STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
AHIMA 2024: Showcasing Top Coding Vendors & HIM Innovations From Black Book Research Annual Industry Survey
AHIMA 2024, taking place this week in Salt Lake City, brings together industry leaders to showcase groundbreaking AI innovations reshaping...
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /...
Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after...
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients...